GlassScriptPhysician profile
Adaku Ogoke
NPI 1184121170
$4,237.52
in general payments reported to CMS, 2019-2025
14 companies · $772 in 2025
The $772 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $492 · 2023: $1,417 · 2024: $1,387 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,576.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $781.94 | 2021-2025 | Sublocade |
| Uswm, LLC | $463.67 | 2021-2023 | Lucemyra, Zimhi |
| Gilead Sciences, INC. | $444.05 | 2023-2025 | Epclusa |
| Braeburn INC. | $427.47 | 2023-2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $420.57 | 2023-2025 | Caplyta |
| Alkermes, INC. | $347.13 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Orexo US, INC. | $282.42 | 2021-2025 | Zubsolv |
| Abbvie INC. | $266.75 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $243.93 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $207.44 | 2022-2023 | Uzedy |
| Otsuka America Pharmaceutical, INC. | $181.70 | 2023-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Lundbeck LLC | $116.67 | 2023-2024 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $32.56 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.22 | 2024 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adaku Ogoke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.